CardiacSense v. Casio: Infringement Action Transferred to New Jersey in 58 Days
CardiacSense Ltd. filed suit against Casio Computer Company in the Eastern District of Texas, asserting US7980998B2 against the G-SHOCK GBDH2000 series of GPS multi-sport watches. Within 58 days, both parties jointly moved to transfer the case to the District of New Jersey under 28 U.S.C. § 1404(a), signalling early strategic alignment on venue.
Early Joint Transfer Signals Agreed Venue Strategy in Wearable Sensor IP Dispute
CardiacSense Ltd., an Israeli medtech company and holder of US7980998B2, filed a patent infringement action on 2 July 2025 in the United States District Court for the Eastern District of Texas against Casio Computer Company, Ltd. The asserted patent covers technology relating to biosensor-integrated GPS multi-sport watches, and CardiacSense targeted Casio’s G-SHOCK GBDH2000 product line — including the GBDH2000-1A, GBDH2000-1A9, and GBDH2000-2 variants — as the accused products.
The case closed just 58 days after filing when Judge Rodney Gilstrap granted a corrected joint motion to transfer the action to the United States District Court for the District of New Jersey pursuant to 28 U.S.C. § 1404(a). The transfer was entirely consensual — both parties represented they had agreed to New Jersey as the new forum. No merits ruling was issued; the Texas court made no determination on infringement, validity, or damages.
The rapidity of the transfer — under two months — suggests the parties may have reached a pre-litigation agreement on venue or that New Jersey presented a more convenient or strategically preferred forum for both sides, possibly related to Casio’s US operational presence. What drove the original Texas filing, and whether the case will proceed vigorously in New Jersey or resolve through settlement, remains unknown from the public record at this stage.
Filing to Case Transferred in 58 days
58 days from filing to transfer — faster than median E.D. Texas venue resolution
Transferred to D. New Jersey: what the venue change means for both parties
28 U.S.C. § 1404(a): what a consensual transfer means
Section 1404(a) permits transfer to any district where the case could have been brought or to which all parties consent, for the convenience of parties and witnesses. Here, the transfer was joint — neither party opposed it. This is distinct from a dismissal: the case survives in full and continues in New Jersey. No rights are waived, no claims extinguished. The Texas court made no substantive ruling.
No merits decidedCardiacSense retains all claims in the new forum
CardiacSense’s infringement claims under US7980998B2 transfer intact to the District of New Jersey. The patent holder loses no rights by the venue change and may benefit from a forum it agreed to — potentially one with more favourable scheduling, juror pool characteristics, or proximity to Casio’s US operations. The merits of the infringement case remain entirely open.
Claims preservedCasio consented — New Jersey may suit its defence strategy
Casio’s consent to New Jersey is notable. It suggests the defendant either has a stronger connection to that district — through its US subsidiary, counsel, or witnesses — or negotiated the transfer as a preferred litigation forum. Casio faces no additional procedural disadvantage from the transfer itself; its invalidity and non-infringement defences remain fully available in the new court.
Defences intactWearable biosensor IP: the real contest begins in New Jersey
For the GPS multi-sport watch sector, this transfer signals that the substantive IP dispute over wearable biosensor patents — specifically claims covering integrated physiological monitoring and GPS tracking in sports wearables — will be adjudicated in the District of New Jersey. Competitors and product teams in the wearable health technology space should monitor the New Jersey docket for claim construction rulings and any validity challenges to US7980998B2.
Monitor NJ docketFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | CardiacSense Ltd | Company | Wearable biosensor medtech company — holder of US7980998B2Search in Eureka ↗ |
| Defendant | Casio Computer Company, Ltd. | Company | Casio Computer Company, Ltd. — manufacturer of G-SHOCK GPS multi-sport watchesSearch in Eureka ↗ |
| Plaintiff counsel | Benjamin Charles Deming | Attorney | Counsel for CardiacSense LtdSearch in Eureka ↗ |
| Plaintiff counsel | Joseph Jude Zito | Attorney | Counsel for CardiacSense LtdSearch in Eureka ↗ |
| Plaintiff law firm | Dnl Zito Castellano | Law Firm | Representing CardiacSense LtdSearch in Eureka ↗ |
| Defendant counsel | John Michael Hardy | Attorney | Counsel for Casio Computer Company, Ltd.Search in Eureka ↗ |
| Defendant law firm | Hardy Cook & Hardy, PC | Law Firm | Representing Casio Computer Company, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge Rodney Gilstrap | Judge | Texas Eastern District CourtSearch in Eureka ↗ |
Official order — verbatim text
The court’s transfer order is purely procedural — Judge Gilstrap granted the joint motion without comment on the merits of CardiacSense’s infringement claims or Casio’s defences. The language ‘all Parties have consented to the District of New Jersey’ is significant: it confirms this was not a contested transfer motion. The infringement action under US7980998B2 is now live in New Jersey, with no Texas findings binding either party on validity, claim scope, or damages.
US7980998B2 — Biosensor-Integrated GPS Multi-Sport Watch Technology
US7980998B2, filed under application number US12/382214, protects technology relating to wearable devices that integrate multiple biosensors — such as heart rate and physiological monitoring — with GPS functionality in a multi-sport watch form factor. The patent’s claims are directed at the combination of sensor array integration, data processing, and GPS tracking in a compact wearable, a technical domain that sits at the intersection of sports performance and medical-grade monitoring. The application date places this invention in the early generation of GPS-enabled health wearables, predating the mass-market smartwatch era.
For the wearable technology sector, US7980998B2 represents early foundational IP in the biosensor-GPS integration space — a category now dominated by major consumer electronics brands. CardiacSense’s decision to assert it against Casio’s premium G-SHOCK GBDH2000 line, which markets 6-sensor GPS multi-sport capabilities, suggests the patentee believes the claims are broad enough to cover current-generation sports watches. If the New Jersey court issues a broad claim construction, the patent could present clearance risk for any brand shipping GPS sports watches with integrated physiological monitoring into the US market.
Should your product team run an FTO against US7980998B2?
Any company designing, manufacturing, or distributing GPS-enabled multi-sport watches with integrated biosensor functionality — including heart rate, SpO2, or physiological monitoring — should treat US7980998B2 as a live clearance risk. The patent is actively asserted, and the New Jersey proceedings will establish claim scope. Product teams launching 6-sensor GPS sports wearables into the US market in particular face direct exposure given the accused product profile in this case.
PatSnap Eureka’s FTO Search Agent can map US7980998B2’s claim language against your product specifications, identify relevant prior art that could support an IPR petition, and flag any continuation or family patents in CardiacSense’s portfolio that may extend coverage. Eureka also monitors the New Jersey docket so your legal team receives automatic alerts when claim construction briefing is filed — the single most consequential event for downstream FTO risk in this dispute.
Run a freedom-to-operate analysis on US7980998B2 to assess your product’s exposure
Run FTO in Eureka →Similar Wearable Biosensor Patent Cases in US District Courts
Cases involving GPS-integrated wearable biosensor patents litigated in US district courts, including E.D. Texas and D. New Jersey, with comparable accused product profiles.
What this case signals for the wearable biosensor IP landscape
A 58-day consensual transfer out of E.D. Texas raises questions about venue strategy and the enforceability of wearable health sensor patents.
E.D. Texas filings do not guarantee E.D. Texas litigation
This case is a reminder that filing in a plaintiff-friendly venue does not lock in that forum. When defendants consent to transfer — or both parties agree — cases can move quickly. IP teams monitoring Casio or wearable tech competitors should track the New Jersey docket (2:25-cv-00674 equivalent) for the substantive proceedings now under way.
US7980998B2 remains live and asserted — FTO exposure persists
The transfer does not resolve CardiacSense’s infringement claims. Any company manufacturing or selling GPS-integrated multi-sport watches with biosensor functionality should assess whether US7980998B2 reads on their products. The patent survived initial proceedings without any validity challenge being adjudicated.
CardiacSense v Casio — key questions answered
CardiacSense filed a patent infringement action against Casio in the Eastern District of Texas on 2 July 2025, asserting US7980998B2 against the G-SHOCK GBDH2000 GPS multi-sport watch line. Within 58 days, both parties jointly moved to transfer the case to the District of New Jersey under 28 U.S.C. § 1404(a). Judge Gilstrap granted the motion on 29 August 2025. No merits ruling was issued in Texas.
CardiacSense asserts US7980998B2 (application number US12/382214), a patent covering biosensor-integrated GPS multi-sport watch technology. The accused products include the Casio G-SHOCK GBDH2000 series — specifically the GBDH2000-1A, GBDH2000-1A9, and GBDH2000-2 variants, all marketed as 6-sensor GPS multi-sport wearables.
The transfer was made pursuant to 28 U.S.C. § 1404(a) on a corrected joint motion filed by both parties. The filing states that all parties consented to the District of New Jersey as the new forum. The public record does not disclose the specific reasons for the consent, but it may relate to Casio’s US operational presence or mutual convenience of the parties and their witnesses.
No. A § 1404(a) transfer is procedural — all claims and defences transfer intact to the new court. CardiacSense’s infringement claims under US7980998B2 remain fully live in the District of New Jersey. The Texas court issued no ruling on validity, infringement, or damages, so neither party has a merits advantage from the transfer itself.
US7980998B2 covers biosensor-integrated GPS wearable technology. CardiacSense’s active assertion against Casio’s G-SHOCK GBDH2000 line suggests the patentee interprets the claims broadly against current-generation 6-sensor GPS sports watches. Any manufacturer or importer of GPS multi-sport wearables with integrated physiological monitoring sold in the US should conduct a freedom-to-operate analysis against this patent, particularly pending claim construction in the District of New Jersey.
PatSnap Eureka searches patents and litigation data to answer instantly.